上海悦心健康集团股份有限公司第八届监事会第十二次会议决议公告

Group 1 - The company held the 12th meeting of the 8th Supervisory Board on May 26, 2025, to discuss various resolutions [2][3] - The Supervisory Board approved the cancellation of unexercised stock options from the first exercise period of the 2023 stock option incentive plan, which will not materially affect the company's financial status or operational results [3][4] - The company will hold its first extraordinary general meeting of shareholders on June 11, 2025, to discuss various proposals, including changes to registered capital and amendments to the Articles of Association [7][8][12] Group 2 - The company plans to use surplus reserves to cover accumulated losses, amounting to approximately 213.91 million yuan, which will reduce the accumulated losses to about 238.26 million yuan after the adjustment [24][25][26] - The company’s wholly-owned subsidiary will inject 600 million yuan into its wholly-owned subsidiary, enhancing its financial structure and reducing the debt ratio [28][29][33] Group 3 - The company approved the cancellation of stock options due to unfulfilled performance conditions, totaling approximately 300.10 million options, which is about 0.33% of the company's total share capital [39][42] - The company’s stock option incentive plan has undergone necessary approvals and will not adversely affect the company's financial status or shareholder interests [44][46] Group 4 - The company will change its registered capital from 922,106,665 yuan to 919,700,965 yuan following the completion of a share buyback program [62] - The company has decided to abolish the Supervisory Board, transferring its responsibilities to the Audit Committee of the Board of Directors [63]